Search Results

Pulmatrix, Inc. announced a series of transactions with MannKind Corporation.

MannKind Corporation announced that it has agreed to in-license iSPERSE™ technology from Pulmatrix for certain indications in exchange for an out-license of MannKind’s Cricket® inhaler to Pulmatrix for inhaled delivery of dihydroergotamine for migraine treatment.

Pulmatrix, Inc. today announced first quarter financial results for 2024 and provided a corporate update on its development programs.

Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM) today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs.

Pulmatrix, Inc. announced publication of, “Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults” in the peer-reviewed publication Headache: The Journal of Head and Face Pain.

Pulmatrix, Inc. announced third quarter financial results for 2023 and provided a corporate update on its development programs.

Pulmatrix today announced that it has entered into a further amendment to its agreement with Cipla for the development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA).

Pulmatrix is currently enrolling patients in a Phase 2 study of PUR1900 in adults with ABPA and Asthma.

Pulmatrix, Inc. today announced the U.S. Food and Drug Administration (“FDA”) has accepted the PUR3100 investigational new drug (“IND”) application and the Company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Evaluate the Safety, Tolerability, and Efficacy of PUR3100 (Dihydroergotamine Mesylate Inhalation Powder) in the Acute Treatment of Migraine.

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2023 and provided a corporate update on its development programs.